Neoplasms

Blood and Lymph Conditions

All Conditions

Rare Diseases

Leukemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Neoplasms by Histologic Type

Hematologic Diseases

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Acute Graft Versus Host Disease

All Drugs and Chemicals

Anti-Infective Agents

Antineoplastic Agents

Antibodies

Cytarabine

Daunorubicin

Immunoglobulins

Antimetabolites

Antiviral Agents

Immunosuppressive Agents

Immunologic Factors

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

7+3 (Standard dose cytarabine for induction and daunorubicin) + SGN-CD33A

High dose cytarabine for consolidation + SGN-CD33A (28-day cycles)

7+3 (standard dose cytarabine for induction and daunorubicin) + SGN-CD33A and High dose cytarabine for consolidation + SGN-CD33A

Standard dose cytarabine for induction

Given intravenously Day 1 or Days 1 and 4 of each cycle

SGN-CD33A

High dose cytarabine for consolidation

Eric Feldman, MD

This study will examine the safety profile of vadastuximab talirine (SGN-CD33A) by itself (monotherapy) or in combination with other standard treatments. The main purpose of this study is to find the best dose and schedule for SGN-CD33A when given in combination with standard induction treatment, in combination with standard consolidation treatment, or by itself for maintenance treatment. This will be determined by observing the dose-limiting toxicities (the side effects that prevent further increases in dose) of SGN-CD33A. In addition, the pharmacokinetic profile and anti-leukemic activity of the study treatment will be assessed.

The study will be conducted in the following distinct parts:

Part A: Induction dose escalation - 7+3 combined with SGN-CD33A (Day 1 and Day 4 dosing)

Part B: Consolidation dose escalation - consolidation combined with SGN-CD33A; up to 4 cycles of consolidation therapy will be administered after SGN-CD33A (Day 1 of each cycle).

Part C: Maintenance - SGN-CD33A Monotherapy; Up to 24 patients with and up to 24 patient without prior allogeneic stem cell transplant will be treated with SGN-CD33A. Both arms will enroll simultaneously. SGN-CD33A will be administered on Day 1 of each 6-week cycle for up to 8 cycles.

Part D: Induction plus consolidation - induction/consolidation combined with SGN-CD33A; patients who achieve a CR/CRi (with or without a second induction) will receive up to 4 cycles of consolidation therapy administered after SGN-CD33A (Day 1 of each cycle).

Part E: Induction dose escalation - 7+3 combined with SGN-CD33A (Day 1 dosing)

A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML

A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia

Seagen Inc.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML	NCT02326584	Acute Myeloid L... Acute Myelogeno...	Standard dose c... SGN-CD33A Daunorubicin High dose cytar...	18 Years -	Seagen Inc.
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML	NCT02326584	Acute Myeloid L... Acute Myelogeno...	Standard dose c... SGN-CD33A Daunorubicin High dose cytar...	18 Years -	Seagen Inc.

Spots Global Cancer Trial Database for standard dose cytarabine for induction